Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.74 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.74 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.74 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.74 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.74 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.74 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.74 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.74 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.74 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | VDR | P11473 | 5/20 | 0.66 |
| ▸ | CASP7 | P55210 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4751618 | 1.00 | GPBAR1 (0.74) | GPBAR1HSD17B10TDP1EPHA2AKR1B10 | |
| SCHEMBL10906860 | 1.00 | GPBAR1 (0.74) | GPBAR1HSD17B10TDP1EPHA2AKR1B10 | |
| SCHEMBL11573739 | 0.91 | GPBAR1 (0.60) | GPBAR1HSD17B10TDP1EPHA2AKR1B10 | |
| SCHEMBL7146262 | 0.90 | GPBAR1 (0.70) | GPBAR1HSD17B10TDP1EPHA2AKR1B10 | |
| SCHEMBL1492095 | 0.88 | GPBAR1 (0.67) | GPBAR1HSD17B10TDP1EPHA2AKR1B10 | |
| Meglumine SCHEMBL23671098 | 0.87 | GPBAR1 (0.57) | GPBAR1HSD17B10TDP1EPHA2AKR1B10 | |
| SCHEMBL1618569 | 0.87 | GPBAR1 (0.54) | GPBAR1HSD17B10TDP1EPHA2AKR1B10 | |
| SCHEMBL19064920 | 0.87 | GPBAR1 (0.54) | GPBAR1HSD17B10TDP1EPHA2AKR1B10 | |
| SCHEMBL11340170 | 0.86 | GPBAR1 (0.56) | GPBAR1HSD17B10TDP1EPHA2AKR1B10 | |
| SCHEMBL977813 | 0.85 | VDR (0.69) | GPBAR1HSD17B10TDP1EPHA2AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538158-B1 | TREATMENT FOR FIBROSIS | GALMED RES AND DEVELOPMENT LTD (IL) | 2023-11-01 | — | — | EP | claimed |
| EP-3538159-B1 | INHIBITION OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS | GALMED RES AND DEVELOPMENT LTD (IL) | 2023-04-05 | — | — | EP | claimed |
| EP-4133266-A1 | IMPROVED METHODS FOR EVALUATING LIVER FUNCTION | Hepquant, LLC (US) | 2023-02-15 | — | — | EP | claimed |
| US-20220362263-A1 | TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS | GALMED RESEARCH AND DEVELOPMENT LTD (IL) | 2022-11-17 | — | — | US | claimed |
| US-11197870-B2 | Treatment for hepatic fibrosis | GALMED RESEARCH AND DEVELOPMENT LTD (IL) | 2021-12-14 | — | — | US | claimed |
| EP-3875596-A1 | METHOD FOR HYDROXYLATION OF STEROIDS | Pharmazell GmbH (DE) | 2021-09-08 | — | — | EP | claimed |
| US-20210169901-A1 | TREATMENT FOR MODULATING GUT MICROBIOTA | GALMED RESEARCH AND DEVELOPMENT LTD. (IL) | 2021-06-10 | — | — | US | claimed |
| EP-3538159-A1 | INHIBITION OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS | Galmed Research and Development Ltd. (IL) | 2019-09-18 | — | — | EP | claimed |
| US-20190275061-A1 | INHIBITION OF FIBROSIS IN NON ALCOHOL FATTY LIVER DISEASE PATIENTS | GALMED RESEARCH AND DEVELOPMENT LTD (IL) | 2019-09-12 | — | — | US | claimed |
| US-20190175619-A1 | TREATMENT OF FIBROSIS, AND INHIBITION OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS | GALMED RESEARCH AND DEVELOPMENT LTD. (IL) | 2019-06-13 | — | — | US | claimed |
| WO-2018087600-A1 | INHIBITION OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS | GALMED RESEARCH AND DEVELOPMENT LTD. (IL) | 2018-05-17 | — | — | WO | claimed |
| WO-2018051180-A1 | TREATMENT FOR DIASTOLIC DYSFUNCTION | GALMED RESEARCH AND DEVELOPMENT LTD. (IL) | 2018-03-22 | — | — | WO | claimed |
| US-20170196891-A1 | FATTY ACID BILE ACID CONJUGATES FOR TREATMENT OF LIPODYSTROPHY | GALMED RESEARCH AND DEVELOPMENT LTD. (IL) | 2017-07-13 | — | — | US | claimed |
| US-20090149537-A1 | Use of Bile Acid or Bile Salt Fatty Acid Conjugates | GALMED INTERNATIONAL LIMITED (MT) | 2009-06-11 | — | — | US | claimed |
| JP-7017867-A | — | — | None | — | — | JP | disclosed |
| EP-3645548-B1 | METHODS FOR PREPARING BILE ACIDS | MEDYTOX INC (KR) | 2023-11-29 | — | — | EP | disclosed |
| EP-3538158-B1 | TREATMENT FOR FIBROSIS | GALMED RES AND DEVELOPMENT LTD (IL) | 2023-11-01 | — | — | EP | disclosed |
| EP-0168229-B1 | PHARMACEUTICAL ANTIFUNGAL COMPOSITION | BTG INTERNATIONAL LIMITED (GB) | 1993-09-15 | — | — | EP | disclosed |
| US-4681876-A | Antifungal utility of bile acids | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1987-07-21 | — | — | US | disclosed |
| EP-0168229-A2 | Pharmaceutical antifungal composition | BTG INTERNATIONAL LIMITED (GB) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275061-A1 | INHIBITION OF FIBROSIS IN NON ALCOHOL FATTY LIVER DISEASE PATIENTS | ACACA, LIPC, CYP46A1 | GPBAR1 165/4885HSD17B10 78/4885TDP1 4796/4885 |
| US-20210169901-A1 | TREATMENT FOR MODULATING GUT MICROBIOTA | NR1H4, SLC10A2, FABP2 | GPBAR1 4/4885HSD17B10 196/4885TDP1 4510/4885 |
| US-20220362263-A1 | TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS | CYP46A1, LPCAT3, NR1H4 | GPBAR1 142/4885HSD17B10 240/4885TDP1 4823/4885 |
| US-11197870-B2 | Treatment for hepatic fibrosis | NR1H4, ACACA, LIPC | GPBAR1 56/4885HSD17B10 131/4885TDP1 4834/4885 |
| US-20170196891-A1 | FATTY ACID BILE ACID CONJUGATES FOR TREATMENT OF LIPODYSTROPHY | CYP27A1, LIPC, SLC27A1 | GPBAR1 93/4885HSD17B10 57/4885TDP1 3289/4885 |
| US-20190175619-A1 | TREATMENT OF FIBROSIS, AND INHIBITION OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS | LIPC, SLC10A1, ACACA | GPBAR1 169/4885HSD17B10 70/4885TDP1 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.